Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

About Intra-Cellular Therapies (NASDAQ:ITCI)

Intra-Cellular Therapies logoIntra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company's bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer's Disease (AD).

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $558.82 million
  • Outstanding Shares: 43,420,000
Average Prices:
  • 50 Day Moving Avg: $11.39
  • 200 Day Moving Avg: $12.95
  • 52 Week Range: $7.85 - $45.20
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.68
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $425,989.00
  • Price / Sales: 1,311.81
  • Book Value: $8.13 per share
  • Price / Book: 1.58
Profitability:
  • EBIDTA: ($117,320,000.00)
  • Net Margins: -27,180.94%
  • Return on Equity: -29.74%
  • Return on Assets: -26.38%
Debt:
  • Current Ratio: 22.78%
  • Quick Ratio: 22.78%
Misc:
  • Average Volume: 793,941 shs.
  • Beta: 0.95
  • Short Ratio: 3.49
 

Frequently Asked Questions for Intra-Cellular Therapies (NASDAQ:ITCI)

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc. (NASDAQ:ITCI) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.12. The business earned $0.10 million during the quarter, compared to the consensus estimate of $0.02 million. Intra-Cellular Therapies had a negative net margin of 27,180.94% and a negative return on equity of 29.74%. During the same quarter in the previous year, the firm earned ($0.64) EPS. View Intra-Cellular Therapies' Earnings History.

Where is Intra-Cellular Therapies' stock going? Where will Intra-Cellular Therapies' stock price be in 2017?

9 equities research analysts have issued 1 year price targets for Intra-Cellular Therapies' shares. Their forecasts range from $10.00 to $75.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $33.14 in the next year. View Analyst Ratings for Intra-Cellular Therapies.

What are analysts saying about Intra-Cellular Therapies stock?

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:

  • 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (5/16/2017)
  • 2. Cantor Fitzgerald analysts commented, "March FDA meeting could highlight path forward. Management noted that a meeting with the FDA is planned for late March, at which submission of the NDA will be discussed. We expect the company to have no specific commentary until the meeting minutes have been reviewed. If a plan to file is announced, we believe the market could de-risk the program to a level lower than that after the first Phase 3 trial data were released. Key to FDA approval will clearly be the robustness of the data presented to the Agency. The track record for schizophrenia drug programs is that not all trials are successful. Third Phase 3 bipolar depression trial in the works. Management noted that a third Phase 3 trial in bipolar depression will be conducted to optimize potential success." We believe such a strategy makes sense considering that, like schiophrenia clinical trials, some failure is not unusual. With an extra" clinical trial ongoing, were one to fail, we believe it reasonable that an NDA would still be filable. Enrollment is expected to complete by the end of 2018." (3/2/2017)
  • 3. Cowen and Company analysts commented, "Today ITCI reported 4Q16 results." (3/1/2017)
  • 4. Piper Jaffray Companies analysts commented, "With Intra-Cellular's 4Q16 call set for Weds., 3/1, we're refreshing our thesis and outlining potential outcomes of this business update. Given the 5 months since data, we'll look for visibility on four key issues: 1. Data-driven insight into factors contributing to the 302 trial failure; 2. Preliminary feedback from the FDA on the 302 trial and lumateperone (ITI-007) program; 3. The clinical and regulatory path forward for luma' over the next 12-18 months; 4. Cash required to execute on these plans." (2/23/2017)

Who are some of Intra-Cellular Therapies' key competitors?

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the folowing people:

  • Lawrence J. Hineline CPA, Chief Financial Officer, Vice President - Finance, Treasurer, Assistant Secretary
  • Robert E. Davis Ph.D., Senior Vice President and Chief Scientific Officer
  • Michael I. Halstead, Senior Vice President, General Counsel, Secretary
  • Kimberly E. Vanover Ph.D., Senior Vice President, Clinical Development
  • Juan F. Sanchez M.D., Vice President - Corporate Communications
  • Allen A. Fienberg Ph.D., Vice President - Business Development
  • Sharon Mates Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Christopher D. Alafi Ph.D., Independent Director
  • Richard Alan Lerner M.D., Independent Director
  • Joel S. Marcus J.D. CPA, Independent Director

Who owns Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.04%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Who sold Intra-Cellular Therapies stock? Who is selling Intra-Cellular Therapies stock?

Intra-Cellular Therapies' stock was sold by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC. Company insiders that have sold Intra-Cellular Therapies stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

How do I buy Intra-Cellular Therapies stock?

Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of Intra-Cellular Therapies stock can currently be purchased for approximately $12.87.


MarketBeat Community Rating for Intra-Cellular Therapies (NASDAQ ITCI)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Intra-Cellular Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intra-Cellular Therapies (NASDAQ:ITCI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $33.14 (157.52% upside)

Analysts' Ratings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Cantor FitzgeraldSet Price TargetBuy$29.00LowView Rating Details
5/2/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralHighView Rating Details
5/2/2017Leerink SwannDowngradeOutperform -> Market Perform$29.00 -> $10.00HighView Rating Details
5/1/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$22.00 -> $10.00HighView Rating Details
3/1/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
12/22/2016BTIG ResearchInitiated CoverageBuy$44.00N/AView Rating Details
9/30/2016Royal Bank Of CanadaReiterated RatingOutperform$74.00 -> $49.00N/AView Rating Details
9/29/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
9/29/2016SunTrust Banks, Inc.DowngradeBuy -> Neutral$60.00 -> $15.00N/AView Rating Details
9/29/2015GuggenheimBoost Price TargetBuy$95.00 -> $104.00N/AView Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for Intra-Cellular Therapies (NASDAQ:ITCI)
Earnings by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Earnings History by Quarter for Intra-Cellular Therapies (NASDAQ ITCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.74)($0.62)$0.02 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.77)($0.64)$0.10 million$0.10 millionViewListenView Earnings Details
11/9/2016Q316($0.84)($0.70)$0.04 million$4.36 millionViewListenView Earnings Details
8/4/2016Q216($0.79)($0.71)$0.02 million$0.23 millionViewN/AView Earnings Details
4/28/2016Q116($0.78)($0.64)$0.02 millionViewListenView Earnings Details
2/25/2016Q415($0.84)($0.67)$0.05 million$30.66 millionViewListenView Earnings Details
11/5/2015Q315($0.66)($0.91)$0.10 millionViewN/AView Earnings Details
8/5/2015Q215($0.72)($0.61)$40.00 million$57.40 millionViewN/AView Earnings Details
4/30/2015Q1($0.68)($0.72)ViewN/AView Earnings Details
3/12/2015Q4 2014($0.49)($0.52)$0.07 millionViewN/AView Earnings Details
11/3/2014Q314($0.34)($0.22)$0.12 millionViewN/AView Earnings Details
8/12/2014Q214($0.24)($0.15)$0.22 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.23)($0.17)$0.17 millionViewN/AView Earnings Details
3/26/2014($0.41)($0.36)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intra-Cellular Therapies (NASDAQ:ITCI)
2017 EPS Consensus Estimate: ($2.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.70)($0.69)($0.70)
Q2 20172($0.69)($0.65)($0.67)
Q3 20172($0.72)($0.66)($0.69)
Q4 20172($0.78)($0.72)($0.75)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intra-Cellular Therapies (NASDAQ:ITCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intra-Cellular Therapies (NASDAQ:ITCI)
Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 67.76%
Insider Trades by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Insider Trades by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2017Lawrence J HinelineVPSell1,918$16.58$31,800.44View SEC Filing  
1/5/2017Michael HalsteadSVPSell1,601$16.55$26,496.55View SEC Filing  
1/5/2017Sharon MatesChairmanSell4,081$16.55$67,540.55View SEC Filing  
12/15/2016Kimberly E VanoverSVPSell9,375$15.23$142,781.25View SEC Filing  
12/7/2016Alafi Capital Co LlcMajor ShareholderBuy65,000$16.27$1,057,550.00View SEC Filing  
11/14/2016Christopher D AlafiDirectorBuy34,000$14.50$493,000.00View SEC Filing  
2/29/2016Christopher D AlafiDirectorBuy100,000$29.70$2,970,000.00View SEC Filing  
12/15/2015Lawrence J. HinelineCFOSell45,000$51.45$2,315,250.00View SEC Filing  
12/11/2015Sharon MatesCEOSell51,500$53.87$2,774,305.00View SEC Filing  
12/8/2015Joel S MarcusDirectorSell92,700$54.47$5,049,369.00View SEC Filing  
11/24/2015Lawrence J HinelineCFOSell5,000$55.00$275,000.00View SEC Filing  
6/8/2015Lawrence P WennogleVPSell25,000$26.84$671,000.00View SEC Filing  
3/11/2015Christopher D AlafiDirectorBuy625,000$24.00$15,000,000.00View SEC Filing  
12/9/2014Lawrence J HinelineCFOSell22,500$16.71$375,975.00View SEC Filing  
12/1/2014Moshe AlafiMajor ShareholderBuy1,422$14.75$20,974.50View SEC Filing  
11/28/2014Christopher D AlafiDirectorBuy35,000$14.75$516,250.00View SEC Filing  
11/19/2014Alafi Capital Co LlcMajor ShareholderBuy1,034$14.25$14,734.50View SEC Filing  
11/18/2014Alafi Capital Co LlcMajor ShareholderBuy3,664$14.26$52,248.64View SEC Filing  
11/13/2014Alafi Capital Co LlcMajor ShareholderBuy12,200$15.34$187,148.00View SEC Filing  
11/6/2014Michael HalsteadSVPBuy20,000$15.38$307,600.00View SEC Filing  
10/15/2014Lawrence P WennogleVPSell3,604$15.00$54,060.00View SEC Filing  
10/13/2014Lawrence P WennogleVPSell1,600$15.00$24,000.00View SEC Filing  
10/8/2014Lawrence P WennogleVPSell4,745$15.00$71,175.00View SEC Filing  
10/6/2014Lawrence P WennogleVPSell16,499$15.00$247,485.00View SEC Filing  
9/15/2014Lawrence P WennogleVPSell5,000$15.00$75,000.00View SEC Filing  
9/8/2014Lawrence J HinelineCFOSell300$15.00$4,500.00View SEC Filing  
5/22/2014Lawrence P WennogleVPSell6,000$15.00$90,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Intra-Cellular Therapies (NASDAQ:ITCI)
Latest Headlines for Intra-Cellular Therapies (NASDAQ:ITCI)
Source:
DateHeadline
globenewswire.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intra-Cellular ... - GlobeNewswire (press release)
globenewswire.com - July 13 at 3:35 AM
finance.yahoo.com logoDEADLINE TODAY: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - July 12 at 12:08 AM
feeds.benzinga.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intra-Cellular Therapies, Inc. (ITCI) and Lead Plaintiff Deadline - July 11, 2017
feeds.benzinga.com - July 11 at 11:46 AM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (NASDAQ:ITCI) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 10 at 10:50 PM
feeds.benzinga.com logoDEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
feeds.benzinga.com - July 10 at 6:49 PM
globenewswire.com logoITCI NOTICE: Rosen Law Firm Reminds Intra-Cellular Therapies, Inc. Investors of Important July 11 Deadline in First ... - GlobeNewswire (press release)
globenewswire.com - July 9 at 10:04 AM
finance.yahoo.com logoITCI  NOTICE: Rosen Law Firm Reminds Intra-Cellular Therapies, Inc. Investors of Important July 11 Deadline in First Filed Class Action – ITCI
finance.yahoo.com - July 8 at 11:53 AM
finance.yahoo.com logo4-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - July 8 at 11:52 AM
finance.yahoo.com logoThe Klein Law Firm Reminds Shareholders of Commencement of a Class Action on Behalf of Intra-Cellular Therapies, Inc. Shareholders and a Lead Plaintiff Deadline of July 11, 2017
finance.yahoo.com - July 7 at 6:35 AM
finance.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intra-Cellular Therapies, Inc. (ITCI) and Lead Plaintiff Deadline - July 11, 2017
finance.yahoo.com - July 7 at 6:35 AM
finance.yahoo.com logoDEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - July 7 at 6:35 AM
finance.yahoo.com logo6-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - July 6 at 6:46 AM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intra-Cellular Therapies, Inc. (ITCI) and Lead Plaintiff Deadline - July 11, 2017
finance.yahoo.com - July 1 at 1:09 AM
finance.yahoo.com logoUPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - July 1 at 1:09 AM
prnewswire.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intra-Cellular Therapies ... - PR Newswire (press release)
www.prnewswire.com - June 30 at 12:24 AM
finance.yahoo.com logoUPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 30 at 12:24 AM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intra-Cellular Therapies, Inc. - ITCI
finance.yahoo.com - June 28 at 7:31 PM
finance.yahoo.com logoAPPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 28 at 7:31 PM
finance.yahoo.com logoAPPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 27 at 6:11 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intra-Cellular Therapies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017 – ITCI
finance.yahoo.com - June 26 at 7:50 PM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 26 at 7:50 PM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Intra-Cellular Therapies Inc.'s FY2018 Earnings (ITCI)
www.americanbankingnews.com - June 26 at 8:54 AM
finance.yahoo.com logoEQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 24 at 4:24 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intra-Cellular Therapies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017 - ITCI
finance.yahoo.com - June 23 at 6:19 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 22 at 6:01 PM
finance.yahoo.com logoIntra-Cellular Therapies, Inc. breached its 50 day moving average in a Bullish Manner : ITCI-US : June 21, 2017
finance.yahoo.com - June 22 at 1:00 PM
finance.yahoo.com logoINVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 22 at 1:00 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intra-Cellular Therapies, Inc. (ITCI) and Lead Plaintiff Deadline: July 11, 2017
finance.yahoo.com - June 22 at 1:00 PM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 20 at 11:56 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 19 at 10:03 PM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of a Class Action on Behalf of Intra-Cellular Therapies, Inc. Shareholders and a Lead Plaintiff Deadline of July 11, 2017
finance.yahoo.com - June 19 at 12:16 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intra-Cellular Therapies, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017 - ITCI
finance.yahoo.com - June 16 at 6:23 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 16 at 6:22 AM
finance.yahoo.com logoIMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 14 at 7:58 PM
americanbankingnews.com logoIntra-Cellular Therapies Inc. (ITCI) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 13 at 10:51 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Intra-Cellular Therapies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2017 - ITCI
finance.yahoo.com - June 12 at 6:34 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 12 at 6:34 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 10 at 1:39 AM
globenewswire.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intra-Cellular ... - GlobeNewswire (press release)
globenewswire.com - June 9 at 8:37 PM
globenewswire.com logoITCI ALERT: Rosen Law Firm Reminds Intra-Cellular Therapies, Inc. Investors of Important Deadline in First Filed ... - GlobeNewswire (press release)
globenewswire.com - June 9 at 8:37 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intra-Cellular Therapies, Inc. of Class Action Lawsuit and Upcoming Deadline – ITCI
finance.yahoo.com - June 9 at 8:37 PM
finance.yahoo.com logoITCI ALERT: Rosen Law Firm Reminds Intra-Cellular Therapies, Inc. Investors of Important Deadline in First Filed Class Action – ITCI
finance.yahoo.com - June 9 at 8:37 PM
feeds.benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Intra-Cellular Therapies, Inc. of Class Action Lawsuit and Upcoming Deadline – ITCI
feeds.benzinga.com - June 9 at 6:18 PM
finance.yahoo.com logoITCI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Intra-Cellular Therapies, Inc. and a Lead Plaintiff Deadline of July 11, 2017
finance.yahoo.com - June 9 at 3:35 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Intra-Cellular Therapies, Inc. (ITCI) and Lead Plaintiff Deadline: July 11, 2017
finance.yahoo.com - June 8 at 6:57 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 8 at 6:57 PM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of Commencement of a Class Action on Behalf of Intra-Cellular Therapies, Inc. Shareholders and a Lead Plaintiff Deadline of July 11, 2017
finance.yahoo.com - June 7 at 5:35 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - June 7 at 5:35 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Intra-Cellular Therapies, Inc. and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - June 7 at 5:35 PM
finance.yahoo.com logoThe Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Intra-Cellular Therapies, Inc. Investors and Encourages Investors to Contact the Firm
finance.yahoo.com - June 6 at 6:32 PM

Social

Chart

Intra-Cellular Therapies (ITCI) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff